Kimberly-ClarkAmbev

Kimberly-Clark vs Ambev

Global maker of tissue and personal care products vs Leading Latin American brewer with extensive distribution network. Which is the better buy for your portfolio in August 2026? Plain-English answer below.

Kimberly-Clark sells the tissue and personal care staples that consumers grab regardless of economic conditions while Ambev dominates beer and soft drink sales across Latin America. Both are consumer ...

Why It’s Moving

Kimberly-Clark

Kimberly-Clark is moving on mixed analyst optimism as growth concerns keep the upside story in check.

  • Analysts are still broadly constructive on Kimberly-Clark, with consensus models showing a moderate upside case, but the signal is mixed rather than emphatic, suggesting investors are weighing stability against slower growth.
  • Recent estimates point to softer North America category momentum and negative organic sales expectations, which can pressure sentiment because it implies limited near-term revenue acceleration even as the company defends margins.
  • The stock remains tied to expectations around cost controls, portfolio simplification, and execution on efficiency gains, so any sign of better-than-expected savings or steadier demand can help support the shares.
Sentiment:
⚖️Neutral
Ambev

Ambev is drawing attention as investors weigh a volume rebound against lingering margin pressure.

  • Ambev’s latest coverage points to a recovery in Brazil beer volumes in 2Q26, which would help offset earlier concerns about softer demand and industry weakness.
  • Citi said the company may be heading into a stronger quarter, suggesting investors are focused on whether volume momentum can translate into better earnings quality.
  • Broader macro noise is also in play, including competition, consumer spending trends, and World Cup-related demand expectations that could lift beverages but also raise comparison risks.
Sentiment:
⚖️Neutral

Investment Analysis

Pros

  • Kimberly-Clark continues to deliver low single-digit growth in adjusted operating profit and organic sales, indicating steady underlying business performance despite recent headwinds.
  • A recently announced $48.7 billion acquisition of Kenvue, owner of Tylenol, could enhance scale, diversify revenue, and strengthen the portfolio in consumer health segments.
  • The company’s share price, having declined significantly over the past year, is trading at a notable discount to analyst price targets and intrinsic value estimates.

Considerations

  • Divestitures such as the exit from the PPE segment and US private-label diaper business will negatively impact reported sales and operating profit growth for the full year.
  • Currency translation and higher net interest expense are forecast to weigh on both operating profit and adjusted earnings per share growth in the near term.
  • Increased competition and innovation pressure in consumer staples may challenge Kimberly-Clark’s ability to maintain market share and margins going forward.
Ambev

Ambev

ABEV

Pros

  • Ambev benefits from a dominant market position in Brazil and a growing footprint across Latin America, providing resilience through economic cycles and demographic trends.
  • The company has a track record of strong cash flow generation, enabling steady investments in marketing, distribution, and premium product launches to drive growth.
  • Ambev’s exposure to fast-growing beer and non-alcoholic beverage segments in Latin America supports long-term revenue expansion potential.

Considerations

  • Volatile currency movements across Latin America, especially the Brazilian real, can materially impact reported financial results and dividend payouts to shareholders.
  • Regulatory risks, including taxation and advertising restrictions on alcohol, remain a persistent challenge in key markets such as Brazil and Argentina.
  • Intensifying competition from both global brewers and local craft brands may pressure Ambev’s pricing power and volume growth in core categories.

Kimberly-Clark (KMB) Next Earnings Date

KMB’s next earnings date is expected on August 4, 2026. The release should cover Q2 2026 results. That timing aligns with the company’s typical late-summer earnings cycle.

Ambev (ABEV) Next Earnings Date

Ambev S.A. (ABEV) is expected to report next on July 30, 2026, based on the latest earnings calendar estimates. The release should cover Q2 2026 results. This date is still an estimate and can shift until the company formally confirms it.

Buy KMB or ABEV in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions

KMB
KMB$109.68
vs
ABEV
ABEV$3.00
Buy ABEV